Overview                                                                                                      Register for Webinar

CRISPR/Cas9 is a powerful tool for the precise modification of gene sequences and the control and detection of gene expression. “CRISPR” refers to clustered regularly interspaced short palindromic repeats.

The CRISPR platform technology utilizes a molecular complex comprised of the protein Cas9, together with one or more guide RNAs, which can be targeted to a desired DNA sequence. 

The CRISPR molecular complex binds to the genome in living cells at any desired locations. By this method, researchers use CRISPR as a “molecular word processor” to specifically alter the DNA sequence at the targeted sites (DNA deletion, insertion or replacement), alter regulation of the target locus, or tag the locus with markers. The CRISPR/Cas9 technology has applications in synthetic biology, plant and animal genomics, biofuels, antibiotics, high-throughput screening, sustainable cosmetics, rapid vaccine development and therapeutic protein production.

Freedom to operate with CRISPR/Cas9 technology begins with a license to the foundational CVC patents available from ERS. Despite the confusion in the US, the CVC patent position in the rest of the world is clearly dominant, including in Europe, Japan, China, and India.

The CRISPR patent portfolio licensed via ERS (known as the CVC portfolio) is the most comprehensive collection of proprietary rights to the fundamental CRISPR/Cas9 gene editing platform. Built on the Nobel Prize winning work of Emmanuelle Charpentier and Jennifer Doudna, ERS grants non-exclusive licenses to a growing list of issued and pending patent applications globally, in all fields excluding direct use as a human therapeutic.

When it comes to the CRISPR/Cas9 patent licensing landscape there is a lot of misinformation in circulation. In this webinar we intend to provide straightforward answers to some of the most common misperceptions. This free webinar will be held online on February 21, 2023 from 3:00 - 5:00 pm. This webinar is free for the attendees and is sponsored by ERS Genomics.

Register Now